Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
|Articles|February 27, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-05-2014
- Volume 10
- Issue 3
Inflammatory Diseases Explained in Artistic Designs
Author(s)Melanie Sena
AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.
Advertisement
The initiative involves more than 200 artists from 40 countries around the world. In addition to professional and independent artists, Perspectives included art studentsfrom more than 15 universities in France, Canada, Italy, and Spain through collaborations with the Polytechnic University of Valencia (Universitat Politecnica de Valencia).
The artistic expressions include, but are not limited to, sculptures, photographs, paintings, and installations. Perspectives will visit various art galleries and medical conferences throughout the world, with additional exhibition dates and locations to be announced.
Source:
Articles in this issue
over 12 years ago
Top 10 Outsourcing Trends in Biopharmaceutical Manufacturingover 12 years ago
Local Knowledge Drives Global Market Expansionover 12 years ago
Regulatory Initiatives Spur API Supply Chain Securityover 12 years ago
Croda Receives Two EXCiPACT Certificationsover 12 years ago
Reaching China's Clinical Trial Marketover 12 years ago
MedImmune Announces Research Collaboration with UC SanFranciscoover 12 years ago
Almac Adds New Blistering TechnologyAdvertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement